Select Language
IDH1
IDH1 Overview
| English Name | Isocitrate dehydrogenase [NADP] cytoplasmic | Approved Drugs | 3 |
| Drugs in Clinical Trials | 11 | Target Synonym | IDH，EC 1.1.1.42，PICD，IDCD，Isocitrate Dehydrogenase (NADP(+)) 1，Isocitrate Dehydrogenase 1 (NADP+)， Soluble，HEL-S-26，IDH1，Isocitrate Dehydrogenase (NADP(+)) 1， Cytosolic，HEL-216，NADP(+)-Specific ICDH，Cytosolic NADP-Isocitrate Dehydrogenase，IDP，NADP-Dependent Isocitrate Dehydrogenase， Cytosolic，Oxalosuccinate Decarboxylase，Epididymis Secretory Protein Li 26，Isocitrate Dehydrogenase 1 (NADP+)，NADP-Dependent Isocitrate Dehydrogenase， Peroxisomal，IDPC，EC:1.1.1.42，Epididymis Luminal Protein 216，Epididymis Secretory Sperm Binding Protein，Isocitrate Dehydrogenase [NADP] Cytoplasmic |
| Highest Development Stage | Approved | ||
| English Name | Isocitrate dehydrogenase [NADP] cytoplasmic |
| Target Synonym | IDH，EC 1.1.1.42，PICD，IDCD，Isocitrate Dehydrogenase (NADP(+)) 1，Isocitrate Dehydrogenase 1 (NADP+)， Soluble，HEL-S-26，IDH1，Isocitrate Dehydrogenase (NADP(+)) 1， Cytosolic，HEL-216，NADP(+)-Specific ICDH，Cytosolic NADP-Isocitrate Dehydrogenase，IDP，NADP-Dependent Isocitrate Dehydrogenase， Cytosolic，Oxalosuccinate Decarboxylase，Epididymis Secretory Protein Li 26，Isocitrate Dehydrogenase 1 (NADP+)，NADP-Dependent Isocitrate Dehydrogenase， Peroxisomal，IDPC，EC:1.1.1.42，Epididymis Luminal Protein 216，Epididymis Secretory Sperm Binding Protein，Isocitrate Dehydrogenase [NADP] Cytoplasmic |
| Approved Drugs | 3 |
| Drugs in Clinical Trials | 11 |
| Highest Development Stage | Approved |
IDH1 Product List
- Product Category
Protein (2)
- Product Status
Launched (2)
- Species
Human (2)
- Tag
His Tag (2)
- Conjugate
Unconjugated (2)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
ID1-H51H6 |  Human | E. coli | Human IDH1 Protein, His Tag (active enzyme, MALS verified) |  |  | |
ID1-H51H8 | Human | E. coli | Human IDH1 (R132C) Protein, His Tag (MALS verified) |  | |
Total: 2
- 1
IDH1 Background
The IDH enzymes catalyze the oxidative decarboxylation of isocitrate to alpha-ketoglutarate (α-KG), producing nicotinamide adenine dinucleotide phosphate (NADPH) in the process via the citric acid cycle. Eukaryotic cells express two distinct classes of IDHs that utilize either NAD or NADP as their cofactors and serve diverse biological functions. NAD-dependent IDH is localized to the mitochondrial matrix and is well known for its central role for energy production in the Krebs cycle. NADP-dependent IDHs are primarily located either in mitochondria or cytoplasm . Each NADP-dependent isozyme is a homodimer. Mutations of Arg132 of human IDH1 result in a reduced ability of the enzyme to convert isocitrate to alpha ‑ketoglutarate, but the enzyme acquires the ability to generate 2-hydroxyglutarate (2HG) from alpha‑ketoglutarate，2-HG is elevated in several tumor types, including a subset of AMLs.
IDH1 Synonyms
IDH1,PICD,IDP
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Safusidenib | DS-1001b; DS-1001; AB-218 | Phase 3 Clinical | Daiichi Sankyo Co Ltd | Astrocytoma; Biliary Tract Neoplasms; Glioblastoma; Glioma; Oligodendroglioma; Solid tumours | Details |
| Ranosidenib | HMPL-306 | Phase 3 Clinical | Glioma; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Solid tumours | Details | |
| TQB-3454 | TQB-3454; CT-2755 | Phase 3 Clinical | Beijing Centaurus Biopharma Co Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Bile Duct Neoplasms; Biliary Tract Neoplasms; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Solid tumours | Details |
| MT-001 | MT-001; MT001 | Phase 2 Clinical | Zhejiang Meton Pharmaceutical Co Ltd | Neoplasms; Solid tumours | Details |
| BAY-1436032 | BAY-1436032 | Phase 1 Clinical | Bayer AG | Leukemia, Myeloid, Acute; Solid tumours | Details |
| IDH-305 | IDH-305 | Phase 1 Clinical | Novartis Pharma Ag | Glioma; Leukemia, Myeloid, Acute; Neoplasms | Details |
| IDH1/2 inhibitor (Eli Lilly) | Phase 1 Clinical | Eli Lilly And Company | Neoplasms | Details | |
| BPI-221351 | BPI-221351 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Glioma; Solid tumours | Details |
| KY-100001 | KY-100001 | Phase 1 Clinical | Kpc Pharmaceuticals Inc | Solid tumours | Details |
| HH-2301 | HH-2301; HH2301 | Phase 1 Clinical | ShangHai HaiHe Biopharma Co Ltd | Biliary Tract Neoplasms; Chondrosarcoma; Glioma; Solid tumours | Details |
| LY-3410738 | LY-3410738 | Phase 1 Clinical | Eli Lilly And Company | Cholangiocarcinoma; Chondrosarcoma; Glioma; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Solid tumours | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Ivosidenib | CS-3010; S-95031; CS 3010; AG-120 | Approved | Agios Pharmaceuticals Inc | 拓舒沃, Tidhesco, Tibsovo, TIBSOVO, Tuoshuvo, Tosuvo | United States | Leukemia, Myeloid, Acute | Servier Pharmaceuticals Llc | 2018-07-20 | Bile Duct Neoplasms; Cholangiocarcinoma; Chondrosarcoma; Ependymoma; Glioma; Hematologic Neoplasms; Hepatic Insufficiency; Hepatoblastoma; Histiocytosis, Langerhans-Cell; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Medulloblastoma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Sarcoma, Myeloid; Solid tumours; Wilms Tumor | Details |
| Vorasidenib | AG-881; AGI-23088; S-95032; S95032 | Approved | Agios Pharmaceuticals Inc | VORANIGO | United States | Astrocytoma; Oligodendroglioma; Glioma | Servier Pharmaceuticals Llc, Laboratoires Servier | 2024-08-06 | Astrocytoma; Ganglioglioma; Glioblastoma; Glioma; Hematologic Neoplasms; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Liver Diseases; Liver Dysfunction; Myelodysplastic Syndromes; Oligodendroglioma | Details |
| Olutasidenib | FT-2102 | Approved | Forma Therapeutics Holdings Inc | Rezlidhia | United States | Leukemia, Myeloid, Acute | Rigel Pharmaceuticals Inc | 2022-12-01 | Chondrosarcoma; Diarrhea; Irritable Bowel Syndrome; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Leukemia, Promyelocytic, Acute; Myelodysplastic Syndromes | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland